- Home
- CCBG vs LBRX Comparison
CCBG vs LBRX Comparison
Compare CCBG & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | LBRX |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.7M | 602.6M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCBG | LBRX |
|---|---|---|
| Price | $46.31 | $24.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $45.00 | ★ $50.67 |
| AVG Volume (30 Days) | 100.0K | ★ 232.7K |
| Earning Date | 04-20-2026 | 05-09-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.17 | N/A |
| P/E Ratio | $12.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.38 | $13.40 |
| 52 Week High | $46.92 | $27.55 |
Technical Indicators
Market Signals| Indicator | CCBG | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.13 | 49.76 |
| Support Level | $41.41 | $22.39 |
| Resistance Level | $46.83 | $27.55 |
| Average True Range (ATR) | 1.00 | 1.65 |
| MACD | 0.39 | 0.08 |
| Stochastic Oscillator | 85.26 | 44.03 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.